Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2016 10:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference

PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
February 17, 2016 14:07 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer,...
February 09, 2016 11:58 ET | Source: Adaptimmune Therapeutics plc

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
February 03, 2016 13:23 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Participate in Two Upcoming Investor Conferences

PHILADELPHIA and OXFORD, United Kingdom, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
February 02, 2016 08:20 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)

PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will...
February 02, 2016 08:16 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trialsCreates opportunity for up to eight combination studies LONDON, PHILADELPHIA...
January 22, 2016 13:07 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces New Additions to Manufacturing Senior Management

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
January 07, 2016 09:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications

PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
December 17, 2015 11:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer

PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
December 03, 2015 09:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Wins Scrip Award for Financing Deal of the Year

PHILADELPHIA and OXFORD, United Kingdom, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...